These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25607727)

  • 1. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.
    Richards JS; Bombardier CH; Wilson CS; Chiodo AE; Brooks L; Tate DG; Temkin NR; Barber JK; Heinemann AW; McCullumsmith C; Fann JR
    Arch Phys Med Rehabil; 2015 Apr; 96(4):680-9. PubMed ID: 25527253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.
    Bombardier CH; Fann JR; Wilson CS; Heinemann AW; Richards JS; Warren AM; Brooks L; Warms CA; Temkin NR; Tate DG
    J Spinal Cord Med; 2014 May; 37(3):247-63. PubMed ID: 24090228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
    Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
    Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
    Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Cunningham LA
    Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Psychometric Properties and Responsiveness to Change of 3 Depression Measures in a Sample of Persons With Traumatic Spinal Cord Injury and Major Depressive Disorder.
    Williams RT; Heinemann AW; Neumann HD; Fann JR; Forchheimer M; Richardson EJ; Bombardier CH;
    Arch Phys Med Rehabil; 2016 Jun; 97(6):929-37. PubMed ID: 26859610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.